Trial Information

Summary: An Open Label Phase I/II Study of Safety and Efficacy of Perifosine and Bortezomib with or without Dexamethasone for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib

You have been asked to participate in this research study because you have multiple myeloma that has either relapsed (come back) or not responded to previous treatment.  The purpose of this study is to evaluate the safety and effectiveness of the investigational drug Perifosine combined with bortezomib in the treatment of multiple myeloma.  Your treatment on this study is expected to last up to 96 days, depending on how your disease responds.  If you complete the 8 cycles, your disease is not worsening on perifosine and bortezomib and you do not have any intolerable side effects, then you may continue to receive the study treatment at your doctor’s discretion.  After your treatment on this study is over, your medical condition will be followed for eight weeks.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 4, 2008 at 1:56:48 PM